{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-23-000036","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.049281+00:00","generated_at":"2026-06-15T06:35:45.231105+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entrada Q1 net loss $6.7M, cash $411.6M; advancing Duchenne pipeline despite clinical hold","bullets":["Cash, cash equivalents and marketable securities $411.6M at March 31, 2023, up from $188.7M at Dec 31, 2022.","Collaboration revenue from Vertex deal $25.3M in Q1; net loss improved to $6.7M from $21.7M in Q1 2022.","Vertex collaboration closed Feb 2023: $224M upfront + $26M equity; eligible for up to $485M milestones plus royalties.","ENTR-601-44 IND on clinical hold with FDA; pursuing global healthy volunteer trial initiation in 2023.","ENTR-601-45 selected as second Duchenne candidate; IND submission planned for Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-23-000036","json":"https://secwatch.observer/filing/0001689375-23-000036.json","markdown":"https://secwatch.observer/filing/0001689375-23-000036.md","text":"https://secwatch.observer/filing/0001689375-23-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000036/0001689375-23-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000036/trda-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:35:45.231105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81ad47c0ccaf514cfc959cb6ddf05e30b7d71ceb","claim":"Entrada Therapeutics, Inc. reported first quarter ending March 31, 2023 results: revenue $25.3 million, net income ($6.7) million.","evidence_excerpt":"development of EEV-therapeutic candidates targeting Duchenne as well as other indications beyond neuromuscular diseases. Collaboration Revenue: Collaboration revenue was $25.3 million for the first quarter of 2023 following the closing of the Vertex Agreement in February 2023. There was no collaboration revenue in the first quarter of 2022. Research &","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000036/0001689375-23-000036-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ending March 31, 2023"},{"label":"Revenue","value":"$25.3 million"},{"label":"Net income","value":"($6.7) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}